<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011100</url>
  </required_header>
  <id_info>
    <org_study_id>CarnoDMCVD</org_study_id>
    <nct_id>NCT02011100</nct_id>
  </id_info>
  <brief_title>Effect of Carnosine on Diabetes and Cardiovascular Risk Factors</brief_title>
  <acronym>Carnorisk</acronym>
  <official_title>Randomised Placebo Controlled Study of the Effect of Carnosine Diabetes and Cardiovascular Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jozef Ukropec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Slovak Academy of Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carnosine is a naturally occurring compound with a potential health benefits. In animal
      studies, carnosine supplementation reduces manifestation of chronic civilization diseases,
      regulates subclinical inflammation, protein glycation and lipid &amp; glucose metabolism. Our
      preliminary data showed the relationship between insulin resistance and carnosine content in
      human skeletal muscle. Based on these unique results we plan to perform intervention study
      aimed at identifying effects of carnosine on insulin sensitivity and secretion, which might
      reduce the development of T2D in obese. Similar metabolic effects of vitamin D3 were
      associated with expression of specific miRNAs. Circulating miRNAs related to carnosine action
      are unknown. The putative positive effects of carnosine on insulin sensitivity and secretion
      in obese patients might have a tremendous impact in prevention of type 2 diabetes.
      Identification of miRNAs associated with carnosine action could provide predictors of
      successful therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>oxidative stress</measure>
    <time_frame>within one year</time_frame>
    <description>AGEs and lipid peroxidation products</description>
  </primary_outcome>
  <primary_outcome>
    <measure>chronic systemic inflammation</measure>
    <time_frame>one year</time_frame>
    <description>circulating hsCRP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>level of glucose intolerance</measure>
    <time_frame>within 10 months</time_frame>
    <description>detected by the oral glucose tolerance test. expressed as 2h glucose, area under the glycemic curve, QUICKI index, HOMA-IR</description>
  </secondary_outcome>
  <other_outcome>
    <measure>muscle carnosine content</measure>
    <time_frame>within 9 months</time_frame>
    <description>assessed by 1H-MRS of muscle in vivo (7T Magnet, Siemens, Germany) it will be expressed relative to creatine signal.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>CARNOSINE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 months oral carnosine administration in a dose of 2 gram per day, twice a day 1 gram dose (1-0-1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 months placebo intake - taken twice a day (1-0-1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carnosine</intervention_name>
    <arm_group_label>CARNOSINE</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI (28-38 kg.m-2);

          -  waist circumference &gt;94 cm;

          -  % body fat 30%

          -  fasting glycemia &lt; 7 mmol/l

        Exclusion Criteria:

          -  age &lt; 25 or &gt; 50 years,

          -  change in body weight &gt; 5 kg in last 12 months,

          -  obesity with BMI &gt; 38kg.m-2,

          -  previously or newly (oGTT) diagnosed type 2 diabetes,

          -  allergy, smoking, alcohol abuse, any pharmacotherapy including regular vitamin intake;

          -  cardiovascular, hematologic, respiratory, gastrointestinal, endocrine or oncologic
             diseases,

          -  kidney disease, acute inflammatory disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jozef Ukropec, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of experimental endocrinology SAS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Ukropcova, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine Comenius University &amp; Institute of Experimental Endocrinology SAS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boris Krahulec, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital in Bratislava</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbora deCourten, MD, MPH, PhD, FRACP</last_name>
    <role>Study Chair</role>
    <affiliation>Monash University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univeristy Hospital in Bratislava</name>
      <address>
        <city>Bratislava</city>
        <zip>81369</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Experimental Endocrinology Slovak Academy of Sciences</name>
      <address>
        <city>Bratislava</city>
        <zip>83306</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2013</study_first_submitted>
  <study_first_submitted_qc>December 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <last_update_submitted>April 14, 2018</last_update_submitted>
  <last_update_submitted_qc>April 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Slovak Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Jozef Ukropec</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

